GlassScriptPhysician profile
Clara E Delgado
NPI 1760868574
$30,907.05
in general payments reported to CMS, 2019-2025
15 companies · $544 in 2025
The $544 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13K · 2022: $3,634 · 2023: $13K · 2024: $751 · 2025: $544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $2,531 · Travel and Lodging: $93.84 · Education: $57.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,500.00 |
| Food and Beverage | $2,531.11 |
| Travel and Lodging | $93.84 |
| Education | $57.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $28,159.73 | 2021-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Medtronic, INC. | $1,442.84 | 2022-2025 | Azure Xt Dr Mri Surescan, Micra, Aurora Ev-Icd Mri Surescan |
| Novo Nordisk INC | $521.60 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $362.36 | 2021-2025 | Mounjaro, Zepbound |
| Amarin Pharma, INC. | $81.02 | 2021-2022 | |
| Abbvie INC. | $63.44 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.97 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $44.44 | 2021-2023 | Farxiga |
| Teva Pharmaceuticals USA, INC. | $36.80 | 2021 | |
| Gilead Sciences, INC. | $31.75 | 2025 | |
| Astellas Pharma US INC | $25.15 | 2025 | Vyloy |
| Amgen INC. | $21.69 | 2021 | |
| Pfizer INC. | $20.30 | 2022 | |
| Merck Sharp & Dohme LLC | $20.00 | 2021 | |
| Paratek Pharmaceuticals, INC. | $12.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clara Delgado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.